NKG2D-ACE2 CAR-NK cell therapy (Sidemu Biotechnology Technology)

N/A

Report date: 2026/03/06 20:02:51

Base Information

Drug NameNKG2D-ACE2 CAR-NK cell therapy (Sidemu Biotechnology Technology)
Drug Alias NameNK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell > Chimeric antigen receptor CIK cell therapyCell and gene therapy > Cell therapy > Source of cells > Umbilical cord blood-derived
Mechanisms of ActionAngiotensin-converting enzyme 2 inhibitorsNKG2-D type II integral membrane protein antagonists
TargetsAngiotensin-converting enzyme 2NKG2-D type II integral membrane protein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Hematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPending
Originator CompaniesChongqing Sidemu Biotechnology Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesChongqing Sidemu Biotechnology Technology Co Ltd
Active IndicationsHematologic Neoplasms
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A